InsiderClue
Stocks · Health care · Orthopedic, Prosthetic & Surgical Appliances & Supplies

REGENTIS BIOMATERIALS LTD.

RGNT Clue Score43
Israel Fiscal year ends December CIK 0001912966
$1.60 -5.88% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.60 −47.63% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 4 Dec 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2023Operating income−1.9Net income−4.1EPS, diluted−24.09Fiscal year 2024Operating income0.9Net income4.8EPS, diluted1.72Fiscal year 2025Operating income−7.0Net income−13.6 −384.3%EPS, diluted−24.16
FY2023FY2024FY2025
Operating income −1.9 0.9 −7.0
Net income −4.1 4.8 −13.6
Growth −384.3%
EPS, diluted −24.09 1.72 −24.16

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2023Operating cash flow−1.2Fiscal year 2024Operating cash flow−0.6Fiscal year 2025Operating cash flow−1.4
FY2023FY2024FY2025
Operating cash flow −1.2 −0.6 −1.4

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Shareholders’ equity−45.9Fiscal year 2024Shareholders’ equity−41.1Fiscal year 2025Cash7.4Shareholders’ equity4.7
FY2023FY2024FY2025
Cash n/a n/a 7.4
Shareholders’ equity −45.9 −41.1 4.7

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024† 31 Dec 2024 FY2025† 31 Dec 2025
Revenue and profit
1.1 0.7 6.6
−1.9 0.9 −7.0
Growth −847.6%
4.1 −4.8 13.6
−4.1 4.8 −13.6
Growth −384.3%
Per share
−24.09 1.72 −24.16
−24.09 1.72 −24.16
Growth −1,504.7%
0.2 2.8 0.6
0.2 2.8 0.6
Growth +1,494.1% −79.5%

† The diluted share count jumps at 2024 and 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 2 of 3 years on file.